prikaz prve stranice dokumenta Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije
  Download
PDF 2.16 MB
master's thesis
Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. urn:nbn:hr:163:478627
Škreblin, Nikolina
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of pharmacology

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Škreblin, N. (2019). Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:478627

Škreblin, Nikolina. "Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. https://urn.nsk.hr/urn:nbn:hr:163:478627

Škreblin, Nikolina. "Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. https://urn.nsk.hr/urn:nbn:hr:163:478627

Škreblin, N. (2019). 'Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 05 November 2024, https://urn.nsk.hr/urn:nbn:hr:163:478627

Škreblin N. Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2019 [cited 2024 November 05] Available at: https://urn.nsk.hr/urn:nbn:hr:163:478627

N. Škreblin, "Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:163:478627

Metadata
TitleFarmakološke mogućnosti u liječenju plućne arterijske hipertenzije
Title (english)Pharmacological Options for the Treatment of Pulmonary Arterial Hypertension
AuthorNikolina Škreblin
MentorLidija Bach-Rojecky (mentor)
Committee memberLidija Bach-Rojecky (predsjednik povjerenstva)
Committee memberŽeljka Vanić (član povjerenstva)
Committee memberMarijana Zovko Končić (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of pharmacology)
Zagreb
Defense date and country2019-06-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
Plućna arterijska hipertenzija je progresivna bolest pluća s vrlo velikom smrtnošću koja je posljedica zatajenja srca. Budući da se javlja rijetko u populaciji, spada u skupinu rijetkih bolesti (orphan diseases). Zahvaljujući napretku u razumijevanju patobiologije u podlozi ove bolesti razvijeni su brojni lijekovi koji djeluju na jedan od tri ključna signalna puta u glatkim mišićnim stanicama krvnih žila pluća – prostaciklinski, endotelinski i put dušik oksida. Tako su glavne skupine lijekova koji se koriste u terapiji antagonisti endotelinskih receptora, inhibitori fosfodiesteraze 5, stimulator topljive gvanilat ciklaze, sintetski analozi prostaciklina i neprostaciklinski agonisti IP receptora. Svi ovi lijekovi smanjuju endotelnu disfunkciju i dovode do vazodilatacije, ali pritom slabo djeluju na vaskularno remodeliranje. Zbog toga su prvenstveno simptomatska terapija koja blago usporava napredovanje bolesti, što je poticaj daljnim istraživanjima novih terapijskih opcija kako bi usporili ili zaustavili progresiju bolesti djelujući na više patofizioloških putova te u konačnici omogućili oboljelima učinkovitiju i sigurniju terapiju te veću kvalitetu života.
Abstract (english)
Pulmonary arterial hypertension is a progressive lung disease with very high mortality resulting from heart failure. It is a very serious disease that occurs rarely in the population and therefore belongs to the group of orphan diseases. Thanks to the progression in understanding the patobiology underlying this disease many new drugs have been developed. Existing approved drugs act on the major signal pathways in smooth muscle cells. Main groups of drugs used in the therapy of pulmonary arterial hypertension are endothelin receptors antagonists, phosphodiesterase 5 inhibitors, stimulators of soluble guanylate cyclase, synthetic analogs of prostacyclin and agonists of IP receptors. All of these drugs reduce endothelial dysfunction and lead to vasodilation, but have little effect on stopping vascular remodeling. Because drugs which have been approved do not cure the disease but only reduce the symptoms further researches continue in order to find new therapeutic options.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:478627
Study programmeTitle: Pharmacy
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-02-24 09:21:34